Digital Invest Inc.
Unleashing Healthcare Transformation with Tailored Treatment Strategies

Every human being carries a unique genetic code that remains unchanged throughout their lifespan. Imagine a healthcare system where diagnoses are no longer generalized and treatments are tailored precisely to the individual’s unique genetic makeup and health profile.

Digital Invest Inc., a biotechnology research company, is determined to make this a reality by offering personalized precision medicine. Its seasoned team of experts, with extensive experience in genetic testing, has developed the Biomath Life Platform, an innovative bio-mathematical platform. Currently in the R&D phase, it analyzes the individual genetic profile and bio-information of the body to develop novel personalized therapies and treatments.

The Biomath Life Platform distinctly combines AI and machine learning to create a specialized database of individual genetic data to create a biomathematical model of the human body, enabling competitive analysis of specific ailments for pre-final diagnosis. Along with accurate diagnosis, the amalgamated data also helps in the manufacturing of personalized medicine for patients and its seamless distribution.

“We are bringing a transformation in medicine by digitally replicating human bodies to simulate their biological composition, enabling us to predict the right treatment outcomes,” says Michael Kofman, CEO and president of Digital Invest Inc.

The biomathematics human model allows Digital Invest Inc. to test its precision medicine multiple times on each model until desired results are achieved. Its platform utilizes AI to consolidate and analyze extensive medical data related to a patient’s condition, culminating in a final decision. It then cross-references this decision with a clinical database and medical records to generate a preliminary diagnosis, which is compared to inputs from hundreds of doctors to improve medical decision-making.

To account for multiple ongoing mutations in the body, Digital Invest Inc.’s platform recalculates and reevaluates an individual’s bio-information every three months and redevelops their prescribed medicine accordingly.

Aiming to make its personalized precision medicine accessible to the masses, Digital Invest Inc. plans to provide memberships or subscription-based plans. Individuals have the flexibility to choose from various subscription plans, including monthly or yearly payment schedules, with their subscription remaining active for their entire lifespan.

A notable aspect of the process architecture and the computational core of Biomath Cloud, as well as Digital Invest Inc.’s business structure, is the ability for each service to function autonomously. This empowers it to integrate partners and provide requested results at any stage of production, as long as mutual collaboration and protocol compatibility exists.

The company’s experience in aggregating and processing big data has taught it to adapt to working with structured and partially structured data and substantial volumes of unstructured data. This allows it to implement machine interfaces between various services and facilitate direct human-machine interaction.

Digital Invest Inc. envisions building a pharmaceutical facility that will have the capacity to house its technology and produce large quantities of personalized pills. A special machine learning algorithm will be used to produce, package and send the pills to each person in an error-free process.

We are bringing a transformation in medicine by digitally replicating human bodies to simulate their biological composition, enabling us to predict the right treatment outcomes

To turn its vision into reality, Digital Invest Inc. has secured exclusive contracts and made significant investments in research and development to streamline the production of individualized medication. It is also forming strategic alliances with industry giants like Illumina, Oracle, Microsoft, and Cisco for DNA sequencing, synchronizing genetic and medical databases, and securely handling large volumes of sensitive information.

It further collaborates with governments, insurance companies, medical clinics, schools, and healthcare professionals to make personalized precision medicine an integral part of everyday healthcare.

Recognizing that this approach requires widespread education, Digital Invest Inc. is actively pursuing partnerships with medical institutions to introduce this groundbreaking concept. It is simultaneously developing a video series aimed at simplifying intricate medical ideas for the general public, offering a glimpse into how its innovative healthcare approach is shaping the future. In pursuit of commercial positioning, it is also developing a tactical white-label platform.

Digital Invest Inc. has created a special department to work together with FDA and other regulatory entities with the goal to address any possible skepticism of its revolutionary approach. It remains steadfast in its quest to find like-minded partners who share its vision and can support its journey.

Building on its visionary ideas by merging cutting-edge advancements in genetics with precision medicine and pharmacology, Digital Invest Inc. is on the brink of making waves in healthcare with therapies tailored to each individual.